ArticleThe Lancet regional health. Western Pacific2025
Epidemiological analysis of infectious diseases in older people in China from 2014 to 2022: a population-based study.
Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epidemiological trends and comparative forecasting models of human brucellosis in inner mongolia autonomous region, mainland China, 2004-2024.PLoS neglected tropical diseases · 2026Article
- Trends in incidence and DALYs of infectious disease from 2000 to 2023 and the attributable risk factors in China: an analysis of the Global Burden of Disease Study 2023.The Lancet regional health. Western Pacific · 2026Article
- Life-course restructuring of infectious mortality in China, 2004-2021: a national surveillance study.Frontiers in public health · 2026Article
- Drug Resistance Patterns, Temporal Trends, and Risk Factors Among Elderly Tuberculosis Patients in Anhui, China: A Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The whole world is undergoing an unprecedented rapid population aging, and the accompanying threat of infectious diseases epidemic among the older people will pose a serious challenge to the national public health. Methods: We extracted individual data on 21 notifiable infectious diseases (NIDs) among individuals aged ≥60 years from the Chinese Infectious Disease Surveillance and Control Project (CISDCP) from 2014 to 2022 in the mainland of China. We comprehensively analyzed the epidemiological characteristics of NIDs in older people and estimated the impact of age, year, and the COVID-19 pandemic. Findings: A total of 8,604,064 cases of 21 major NIDs were reported, with an overall annual incidence of 362·10/100,000. Sexually transmitted or bloodborne diseases (STBDs, 45·23%) were the most common diseases. Notably, ranking of syphilis rose from fourth to third, while HIV/AIDS moved from eighth to seventh; respiratory diseases (34·88%) showed sustained declines. Tuberculosis remained the most common respiratory diseases despite a 6·4% annual decline (APC, P < 0·001); gastrointestinal or enteroviral diseases (GEDs, 18·35%) showed sustained declines, except for infectious diarrhea and hepatitis E; vector-borne or zoonotic diseases (VBZDs, 1·54%) remained low, though brucellosis increased during COVID-19 pandemic. Inflection point analysis revealed that 13 diseases, such as tuberculosis, infectious diarrhea, hepatitis B, and others, exhibited a quadratic distribution (inverted "V" shape) in age-specific incidence as age increased. Difference was noticeable between regions, with the older people in Inner Mongolia-Xinjiang region and South China region continuing to carry a disproportionate burden from NIDs. Interpretation: Although China's success in infectious disease control in older people. Effective prevention and control strategies are needed for highest incidence diseases, such as tuberculosis, hepatitis B, and infectious diarrhea, especially in high-incidence regions and among critical age points. Funding: National Major Research & Development Program of China (2022YFC2604000).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.